The Valley Desk

Clinical trial reportBlood advancesPublished

Teclistamab and daratumumab immune-based doublet therapy for relapsed/refractory multiple myeloma: the TRIMM-2 study

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
Blood advances
Published
Subject terms
Humans; Multiple Myeloma; Recurrence; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Bispecific; Antibodies, Monoclonal; Treatment Outcome; Adult; Aged; Aged, 80 and over; Middle Aged; Female
PubMed ID
42685673
PubMed Central ID
PMC13782887
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal